Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ELCC 2022 | IFCT-1803 LORLATU cohort: real-world evidence supporting lorlatinib in ALK+ NSCLC

Nicolas Girard, MD, PhD, Institut Curie, Paris, France, discusses the results of the IFCT-1803 LORLATU cohort (NCT03727477) assessing treatment sequencing, and lorlatinib safety and efficacy in patients with ALK- and ROS1-positive non-small cell lung cancer (NSCLC). The real-world evidence demonstrated lorlatinib provides a notable clinical benefit in heavily pretreated patients with ALK-positive NSCLC. This interview took place during the virtual European Lung Cancer Congress 2022.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.